期刊文献+

四种激素制剂用于绝经期激素补充治疗的比较

Comparative study with four agents hormone replacement therapy in postmenopausal women
暂未订购
导出
摘要 目的 :比较 4种用于激素补充治疗的制剂的疗效和副作用 ,为选择用药提供参考。方法 :96例绝经妇女随机分为 4组 ,各服用克龄蒙、尼尔雌醇、妇复春和妇舒宁 6个月。用药前、后观察绝经期症状 ,检测血总胆固醇 (CHOL)、甘油三酯 (TG)、高密度脂蛋白 (HDL)和低密度脂蛋白(LDL)、骨密度及子宫内膜厚度。结果 :用药后 4组之绝经期症状均明显改善 ,Kupperman评分显著下降 ;除尼尔雌醇组TG下降及妇复春组HDL上升无统计学意义外 (P >0 0 5 ) ,其余各组CHOL、TG及LDL均明显下降 ,HDL明显上升 (P <0 0 5或 0 0 1) ;4组之骨密度均无明显变化 (P >0 0 5 ) ;无 1例宫内膜过度增生。对上述指标之影响 ,4种制剂间相比较无显著性差异 (P >0 0 5 )。结论 :4种制剂均能显著改善绝经期症状 。 Aim: To compare the effect of four agents hormone replacement therapy in postmenopausal four agents hormone replacement therapy in postmenopausal women for choosing agent. Methods: 96 cases were divided into four groups randomly, Climen group,Nilestriol (CEE 3) group,Fufuchun group and Oesclim group,hormone replacement therapy for 6 months. Climacteric symptoms,four lipoproteins cholesterin (CHOL), triglycerin (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), bone mineral density (BMD) and the thicknes of endometrium were evaluated before and 6 months after treatment. Results: After 6 months, Kupperman score decreased significantly all groups (P<0.01),except CEE 3 group TG decreased and Fufuchun group HDL increased no significance statisticlly (P>0.05),CHOL?TG?LDL decreased and HDL increased significantly all groups (P<0.05 or <0.01). BMD no changed significantly four groups all (P>0.05). None endometrial hyperplasia . The above changes are not obvious significance statisticlly between four groups (P>0.05). Conclusion: Four agents can improve significantly in climacteric symptoms,are beneficial to lipoproteins metabolism and restrain bone loss in postmenopausal women.
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 2002年第4期35-39,共5页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 珠海市科委立项课题 (No .992 0 )
关键词 激素补充治疗 绝经期症状 脂蛋白 骨密度 hormone replacement therapy climacteric symptoms lipoprotein bone mineral density
  • 相关文献

参考文献6

二级参考文献17

  • 1刘建立,樊薇.尼尔雌醇对绝经后子宫内膜的影响[J].中华妇产科杂志,1993,28(2):76-78. 被引量:26
  • 2葛秦生.绝经后激素替代治疗[J].生殖医学杂志,1993,2:195-195.
  • 3[1]Albrigt F, Rifenstem C. The parathyroid glands and metabolic bone disease. Baltimone: William and Wilkins Company, 1948.78.
  • 4[2]Herschberger LG, et al. Myotrophic activity of 19 nortestosterone and other steroids determined by the modified levator muscle method. Proc Soc Exp Biol Med,1953,83:175-180.
  • 5[3]Markiewisz L, Gurpide E. In vitro evaluation of estrogenic,estrogenic antagonistic effects of a steroidal drug (Org OD14)and its metabolites on human endometrium. J Steroid Biochem,1990,35:535-541.
  • 6[4]Rymer J, et al. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int,1994,4:314-317.
  • 7[5]Gompel A, et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol,1997,11(Suppl1):77-79.
  • 8[6]Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet, 1997,350:1047-1059.
  • 9[7]Bjamason NH, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab,1997,82:1752-1756.
  • 10[8]Haenggi W, et al. Long-term influence of different postmenopausal hormone replacemnt regimes on serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol,1997,104:708-717.

共引文献3170

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部